Status:
COMPLETED
A Study to Evaluate the Use of Apremilast in Patients With Psoriatic Arthritis, Naïve to Biological Treatment
Lead Sponsor:
Amgen
Conditions:
Arthritis, Psoriatic
Eligibility:
All Genders
18+ years
Brief Summary
Observational, prospective and multicenter study in approximately 25 sites nationwide. The investigators participating in this study will be rheumatologists specializing in this pathology. The study ...
Eligibility Criteria
Inclusion
- Men and women older than 18 years.
- Patients diagnosed with psoriatic arthritis according to the CASPAR criteria\*.
- Patients who, following the routine clinical practice, initiated treatment with apremilast 6 months (±4 weeks) before their inclusion in the study.
- Patients naive to biologic treatments.
Exclusion
- Patients who reject to sign the informed consent.
- Patients enrolled in a clinical trial within the 4 weeks preceding the baseline visit or for the duration of apremilast treatment.
Key Trial Info
Start Date :
February 6 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 20 2021
Estimated Enrollment :
119 Patients enrolled
Trial Details
Trial ID
NCT03828045
Start Date
February 6 2019
End Date
October 20 2021
Last Update
June 5 2024
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
H Son Espases
Mallorca, Balearic Islands, Spain, 07120b
2
H Son Llatzer
Mallorca, Balearic Islands, Spain, 07198
3
H Txagorritxu de Vitoria
Vitoria-Gasteiz, Basque Country, Spain, 01009
4
H Univ Canarias
Santa Cruz de Tenerife, Canary Islands, Spain, 38320